NCT04868890: A reported trial by Ampio Pharmaceuticals. Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04868890 |
|---|---|
| Title | A Randomized, Double-Blinded, Placebo-Controlled Phase II Study to Evaluate the Safety and Efficacy of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19 |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 22, 2021 |
| Completion date | Feb. 16, 2022 |
| Required reporting date | Feb. 16, 2023, midnight |
| Actual reporting date | Oct. 27, 2022 |
| Date last checked at ClinicalTrials.gov | June 15, 2026 |
| Days late | None |